

## News Releases

All Years

Search

Go

[Advanced Search](#)

**JUN 15, 2026**

**Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma**

**MAY 14, 2026**

**Inhibrx Reports First Quarter 2026 Financial Results**

**MAY 11, 2026**

**Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy**

**MAY 8, 2026**

**Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC**

**APR 21, 2026**

**Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer**

**APR 20, 2026**

**Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer**

**MAR 19, 2026**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial**

## **Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results**

**MAR 2, 2026**

## **Inhibrx Announces Participation in Upcoming Scientific Conference**

**DEC 16, 2025**

## **Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program**

**NOV 14, 2025**

## **Inhibrx Reports Third Quarter 2025 Financial Results**

**NOV 4, 2025**

## **Inhibrx Announces Participation in Upcoming Scientific Conferences**

**OCT 23, 2025**

## **Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts**

**OCT 22, 2025**

## **Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts**

**AUG 13, 2025**

## **Inhibrx Reports Second Quarter 2025 Financial Results**

**MAY 14, 2025**

**Inhibrx Reports First Quarter 2025 Financial Results**

**APR 1, 2025**

**Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President**

**MAR 17, 2025**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results**

**JAN 21, 2025**

**Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer**

**JAN 13, 2025**

**Inhibrx Biosciences Announces Loan Agreement with Oxford Finance**

**NOV 14, 2024**

**Inhibrx Biosciences Reports Third Quarter 2024 Financial Results**

**NOV 4, 2024**

**Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation**

**AUG 13, 2024**

**Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights**

**MAY 24, 2024**

**Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi**

**MAY 10, 2024**

**Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off**

**MAY 8, 2024**

**Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger**

**FEB 28, 2024**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results**

**JAN 23, 2024**

**Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to \$2.2B**

**NOV 9, 2023**

**Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights**

**NOV 2, 2023**

**Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma**

**OCT 18, 2023**

**Inhibrx Announces Participation in Upcoming Scientific Conferences**

**AUG 29, 2023**

**Inhibrx Announces \$200 Million Private Placement Financing**

**AUG 7, 2023**

**Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights**

**MAY 30, 2023**

**Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency**

**MAY 8, 2023**

**Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights**

**MAR 6, 2023**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results**

**JAN 4, 2023**

**NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates**

**NOV 18, 2022**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**NOV 16, 2022**

**Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma**

**NOV 7, 2022**

**Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights**

**OCT 20, 2022**

**Inhibrx Announces Participation in Upcoming Scientific Conferences**

**AUG 15, 2022**

**European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma**

**AUG 8, 2022**

**Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights**

**JUN 30, 2022**

**Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance**

**MAY 19, 2022**

**Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting**

**MAY 12, 2022**

**Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency**

**MAY 9, 2022**

**Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights**

**MAR 24, 2022**

**Inhibrx Announces Details of Presentations at 2022 AACR Annual**

## Meeting

**FEB 28, 2022**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights**

**FEB 22, 2022**

**Inhibrx Announces Amended Loan Agreement with Oxford**

**JAN 4, 2022**

**Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data**

**DEC 1, 2021**

**Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma**

**NOV 9, 2021**

**Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights**

**NOV 3, 2021**

**Inhibrx Announces Presentations at SITC 2021**

**NOV 1, 2021**

**Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences**

**OCT 28, 2021**

**Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors**

**TO ITS BOARD OF DIRECTORS**

**SEP 13, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**AUG 9, 2021**

**Inhibrx Reports Second Quarter 2021 Financial Results**

**JUN 21, 2021**

**Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford**

**MAY 17, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conferences**

**MAY 13, 2021**

**Inhibrx Reports First Quarter 2021 Financial Results**

**MAR 12, 2021**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist**

**FEB 1, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**JAN 13, 2021**

**Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional**

## Treatment of Chondrosarcoma or Metastatic Conventional Chondrosarcoma Patients

**JAN 5, 2021**

**Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist**

**NOV 13, 2020**

**Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford**

**NOV 11, 2020**

**Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients**

**NOV 5, 2020**

**Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences**

**AUG 21, 2020**

**Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares**

**AUG 18, 2020**

**Inhibrx Announces Pricing of Initial Public Offering of Common Stock**

**JAN 8, 2020**

**Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40**

**SEP 3, 2019**

## **Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5**

**MAY 21, 2019**

**Inhibrx Announces \$40M Investment from Viking Global Investors**

**FEB 19, 2019**

**Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody**

**JAN 7, 2019**

**bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies**

**DEC 6, 2018**

**Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)**

**OCT 31, 2017**

**Inhibrx Wins CARB-X Award Of Up To \$6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections**

**SEP 15, 2015**

**Inhibrx and The Alpha-1 Project Collaborate to Develop a Recombinant Alpha-1 Antitrypsin with Improved Properties**

**JUN 27, 2012**

**Inhibrx announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program**

Show  per  
page



<https://inhibrx.investorroom.com/news-releases?l=100>